Acadia Pharmaceuticals (ACAD) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD’s commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).Acadia’s first drug, Nuplazid, is the first and the only FDA-approved treatment for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. Its second ...